Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Optimal genome profiling for re-biopsy of TKI resistant tumour

Date

08 Oct 2016

Session

Definition and management of oligoprogression during treatment with TKI inhibitors

Presenters

Keith Kerr

Authors

K. Kerr

Author affiliations

  • Aberdeen Royal Infirmary, AB25 2ZN - Aberdeen/GB
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Resources from the same session

The perspective of the oncologist

Presenter: Egbert Smit

Session: Definition and management of oligoprogression during treatment with TKI inhibitors

Resources:

Presentation

Practicalities and risks of biopsy

Presenter: Josephine Barry

Session: Definition and management of oligoprogression during treatment with TKI inhibitors

Resources:

Presentation

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings